

May 31, 2018



# CV Sciences, Inc. Supports World No Tobacco Day on May 31, 2018

LAS VEGAS, May 31, 2018 (GLOBE NEWSWIRE) -- [CV Sciences, Inc.](#), (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we"), is pleased to announce its support in highlighting the World Health Organization (WHO) and its partners in the annual [World No Tobacco Day](#) on May 31, 2018. This year, the theme is "Tobacco Breaks Hearts," referencing a study that tobacco is responsible for more than one in ten deaths caused by cardiovascular disease.

World No Tobacco Day notably features the health risks associated with tobacco use and advocates for effective policies to reduce tobacco consumption. The theme for 2018 is based around the link between tobacco and heart and other cardiovascular diseases, such as strokes, which combined are one of the world's leading causes of death.

Smoking is associated with around 7 million global deaths per year and is a major risk factor for myocardial infarction, stroke, heart failure and low quality of life. According to the WHO, utilizing the slogan, "Tobacco Breaks Hearts", sheds light on the relation between tobacco and cardiovascular health with the goal of reducing cardiovascular disease worldwide. Tobacco use also threatens the health of populations globally and restricts development at many levels from economic growth, education, poverty, and the environment.

CV Sciences is developing a proprietary drug - CVSI-007 - combining cannabidiol (CBD) and nicotine for the treatment of smokeless tobacco use and addiction. While most believe that smoking is the only deadly form of tobacco use, smokeless tobacco is extremely addictive and has surpassed smoking in rate of growth as a cause of death from tobacco use. Currently, there is no FDA-approved drug that is indicated for treatment of smokeless tobacco cessation. CV Sciences is developing CVSI-007 to fill an unmet patient need for treating nicotine addiction.

## **About CV Sciences, Inc.**

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting [www.cvsciences.com](http://www.cvsciences.com).

## **FORWARD-LOOKING DISCLAIMER**

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such

forward-looking statements by definition involve risks, uncertainties.

**CONTACT INFORMATION:**

Robert Haag  
Managing Director  
IRTH Communications  
[CVSI@irthcommunications.com](mailto:CVSI@irthcommunications.com)  
866-976-4784



Source: CV Sciences, Inc.